@auditor112017 Avatar @auditor112017 Auditor

Auditor posts on X about $ions, $sgmo, $biib, $lly the most. They currently have [---] followers and [---] posts still getting attention that total [--] engagements in the last [--] hours.

Engagements: [--] #

Engagements Line Chart

Mentions: [--] #

Mentions Line Chart

Followers: [---] #

Followers Line Chart

CreatorRank: undefined #

CreatorRank Line Chart

Social Influence

Social category influence stocks 36.28% currencies 7.96% finance 5.31% cryptocurrencies 4.42% countries 0.88% fashion brands 0.88%

Social topic influence $ions #24, $sgmo #21, $biib 11.5%, $lly 10.62%, $azn 7.96%, $arwr 7.96%, $qure 7.08%, $alny 6.19%, $rhhby 3.54%, $tak 2.65%

Top accounts mentioned or mentioned by @artsstocks @biotechanalysst @francaole @yusufhameed @zinselmeyerb @rnaianalyst @ionispharma @mchilberg @aamortazavi @gamalielbaer @ttramyloid @jimcramer @trendingbitcoin @junglejorge2 @usfda @aaronrosenblum5 @bearsbounce @seedy19tron @johncendpts @martymakary

Top assets mentioned Ionis Pharmaceuticals, Inc. Common Stock (IONS) Biogen Inc (BIIB) Eli Lilly and Company (LLY) AstraZeneca PLC (AZN) Arrowhead Research Corporation (ARWR) uniQure N.V. (QURE) Alnylam Pharmaceuticals, Inc. (ALNY) Intellia Therapeutics, Inc (NTLA) Metagenomi Technologies, LLC (MGX) Bitcoin (BTC) Novartis AG (NVS) Vertex Protocol (VRTX) Praxis Precision Medicines, Inc. (PRAX) Pfizer, Inc. (PFE) Synthetify (SNY) Amgen, Inc. (AMGN) BEAM (BEAM)

Top Social Posts

Top posts by engagements in the last [--] hours

"Could [----] be the year for $sgmo https://www.cnbc.com/video/2026/01/09/heath-care-momentum-not-just-driven-by-glp-1s-says-mizuhos-holz.html https://www.cnbc.com/video/2026/01/09/heath-care-momentum-not-just-driven-by-glp-1s-says-mizuhos-holz.html"
X Link 2026-01-09T23:09Z [---] followers, [---] engagements

"$ions Wondering what these [--] targets would be"
X Link 2025-12-28T18:04Z [---] followers, [---] engagements

"$ions $biib"
X Link 2026-02-05T17:29Z [---] followers, [---] engagements

"There could be a possibility that $sgmo is not getting the high upfront that they are asking especially if its Astellas due to the very weak yen. Could be agreeing with a much lower upfront and have to streamline operations to make the funds last longer"
X Link 2026-01-25T17:25Z [---] followers, [---] engagements

"$ions $biib Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy https://finance.yahoo.com/news/nature-medicine-publishes-results-pivotal-123000437.html https://finance.yahoo.com/news/nature-medicine-publishes-results-pivotal-123000437.html"
X Link 2026-02-05T17:26Z [---] followers, [---] engagements

"$ions $bcyc Conjugation to a transferrin receptor 1-binding Bicycle peptide enhances ASO and siRNA potency in skeletal and cardiac muscles https://pmc.ncbi.nlm.nih.gov/articles/PMC11983102/ https://pmc.ncbi.nlm.nih.gov/articles/PMC11983102/"
X Link 2026-02-06T23:41Z [---] followers, [---] engagements

"$sgmo $qure UniQure pauses Fabry gene therapy dosing in [--] groups after toxicities emerge https://www.fiercebiotech.com/biotech/uniqure-pauses-fabry-gene-therapy-dosing-2-groups-after-toxicities-emergeutm_medium=email&utm_source=nl&utm_campaign=LS-NL-FierceBiotech&oly_enc_id=6410A8494378C6A https://www.fiercebiotech.com/biotech/uniqure-pauses-fabry-gene-therapy-dosing-2-groups-after-toxicities-emergeutm_medium=email&utm_source=nl&utm_campaign=LS-NL-FierceBiotech&oly_enc_id=6410A8494378C6A"
X Link 2026-02-07T01:28Z [---] followers, [----] engagements

"@yusufhameed @BPharmCatalyst @DrMakaryFDA @jimcramer $SNY must be regretting not to keep ST-920. $sgmo"
X Link 2026-02-02T17:38Z [---] followers, [---] engagements

"@ZinselmeyerB @Prof_Dollar Does $qure Fabry IV administration require preconditioning $sgmo"
X Link 2026-02-06T16:57Z [---] followers, [---] engagements

"@BiotechAnalysst Are potential partners waiting for $qure Fabry data to decide on closing the Fabry deal or not $sgmo"
X Link 2026-02-06T18:54Z [---] followers, [---] engagements

"@TrendingBitcoin Why would people want to by bitcoin when they can have tokenized gold"
X Link 2026-02-07T03:59Z [---] followers, [---] engagements

"@TrendingBitcoin Instead of pushing for bitcoin the future is in blockchain and tokenization"
X Link 2026-02-07T04:02Z [---] followers, [---] engagements

"@anssiapina @BiotechAnalysst Interesting to see that $qure started the trial with the highest dose and next with the lowest dose with the smallest n=3 $sgmo"
X Link 2026-02-07T20:49Z [---] followers, [---] engagements

"@ZinselmeyerB @day_startup @Franca_ole @Pharmdca I would not be surprised more companies are interested in their new capsid since no other capsids have shown superior delivery. ZF payload delivery could also be a consideration. $nvs $lly $azn $tak and others are likely in talks with $sgmo"
X Link 2025-03-23T20:44Z [---] followers, [---] engagements

"@yusufhameed Trump mentioned pharmaceutical drug manufacturing will be coming back to U.S. this morning. Not sure if Thermo Fisher has to build manufacturing here like the foreign car manufacturers. $sgmo"
X Link 2025-03-24T19:39Z [---] followers, [---] engagements

"@ZinselmeyerB @Franca_ole @yusufhameed Seems like the timing of $lly deal was based on the new capsid that $sgmo was working on. $sgmo has developed the new capsid last yr. Likely $lly has completed evaluating it by now and ready to followup on the deal"
X Link 2025-03-25T16:20Z [---] followers, [---] engagements

"@ZinselmeyerB @Franca_ole @yusufhameed $sgmo $lly How many CNS targets are they going after https://www.fiercebiotech.com/biotech/stroke-good-luck-sangamo-biotech-snags-1b-biobucks-deal-lillys-prevail-after-layoffs-2 https://www.fiercebiotech.com/biotech/stroke-good-luck-sangamo-biotech-snags-1b-biobucks-deal-lillys-prevail-after-layoffs-2"
X Link 2025-03-25T16:31Z [---] followers, [---] engagements

"@ZinselmeyerB @Franca_ole @yusufhameed It seems like $sgmo had already received the upfront payment from $lly"
X Link 2025-03-25T16:46Z [---] followers, [---] engagements

"@ZinselmeyerB @Franca_ole @yusufhameed The new capsid deal that SM talked about could be from another big pharma. $sgmo"
X Link 2025-03-25T16:49Z [---] followers, [---] engagements

"@yusufhameed @BiotechAnalysst @SangamoTx @jimcramer Unfortunate for $sgmo $biib has a new CEO with different goals. The new CEO does not have a vision to treat CNS diseases. He thinks it takes too long to run the CTs. Now all their investments are benefiting other companies"
X Link 2025-03-26T13:38Z [---] followers, [---] engagements

"@ionispharma How much is the upfront payment $ions @ionispharma"
X Link 2025-03-26T13:45Z [---] followers, [--] engagements

"@ZinselmeyerB @UnionSteel2017 @BiotechAnalysst Love your speculation But it makes sense to confirm what they are seeing to get a more powerful dataset. I was thinking some patients may have dropped out but shouldn't be that many in this small sample. $sgmo"
X Link 2025-03-27T00:18Z [---] followers, [---] engagements

"@mchilberg The capsid Prevail is using is for intrathecal delivery. Did Prevail signed a deal for an older capsid from $sgmo and not the one to cross the BBB"
X Link 2025-03-27T16:44Z [---] followers, [---] engagements

"@mchilberg $sgmo Looks like the Prevail/ $lly deal was done in July/2023. $sgmo didn't announce the new capsid until early [----]. If Prevail has the old capsid they could be coming back for the new capsid https://www.fiercebiotech.com/biotech/stroke-good-luck-sangamo-biotech-snags-1b-biobucks-deal-lillys-prevail-after-layoffs-2 https://www.fiercebiotech.com/biotech/stroke-good-luck-sangamo-biotech-snags-1b-biobucks-deal-lillys-prevail-after-layoffs-2"
X Link 2025-03-27T16:57Z [---] followers, [---] engagements

"@BiotechAnalysst I don't believe SM gave a firm deadline for closing the deal. He did say "I hope." . This could mean by the eom or a week or [--] later. But for sure a deal is coming $sgmo"
X Link 2025-03-27T19:54Z [---] followers, [---] engagements

"@ZinselmeyerB @mchilberg Do you think it includes testing of the new BBB crossing capsid"
X Link 2025-03-27T20:00Z [---] followers, [--] engagements

"$ions $biib ASO is laying the ground work for $sgmo/ $rhhby on their Tau program Ph2 data read out next yr will be closely watched. https://www.crweworld.com/article/news-provided-by-globenewswire/3620963/biogens-investigational-tau-targeting-therapy-biib080-receives-fda-fast-track-designation-for-the-treatment-of-alzheimers-disease https://www.crweworld.com/article/news-provided-by-globenewswire/3620963/biogens-investigational-tau-targeting-therapy-biib080-receives-fda-fast-track-designation-for-the-treatment-of-alzheimers-disease"
X Link 2025-04-02T16:53Z [---] followers, [----] engagements

"$ions $biib $sgmo $rhhby Targeting MAPT to reduce the production of tau protein $ions and $sgmo both are using this strategy"
X Link 2025-04-03T17:21Z [---] followers, [---] engagements

"$lly previously had paid an upfront for some older capsids. This could be a goodwill gesture from $lly. $sgmo"
X Link 2025-04-03T20:19Z [---] followers, [---] engagements

"With $lly signing on look for $tak and $azn to follow $sgmo"
X Link 2025-04-03T20:24Z [---] followers, [---] engagements

"$sgmo $lly Looks like $lly likes what they have seen in $sgmo BBB crossing capsids from 2023's capsids evaluation deal and moved today to license the capsid This is a big confirmation from a blue-chip pharma https://www.fiercebiotech.com/biotech/stroke-good-luck-sangamo-biotech-snags-1b-biobucks-deal-lillys-prevail-after-layoffs-2 https://www.fiercebiotech.com/biotech/stroke-good-luck-sangamo-biotech-snags-1b-biobucks-deal-lillys-prevail-after-layoffs-2"
X Link 2025-04-03T22:21Z [---] followers, [---] engagements

"$sgmo has two more likely capsid deals to come: Alexion/ $azn and $tak. They'll need the BBB crossing capsid to deliver the ZF cargo With $lly on-board it should help get rid of their hesitation about the tech"
X Link 2025-04-04T01:16Z [---] followers, [---] engagements

"@SchoolyardPS7 @ZinselmeyerB @Barclays In [--] yrs milestone payments will come when $rhhby and $lly start their clinical trials recurring revenue from Fabry sales and Hem A could contribute to the bottom line. We may be talking about T-reg in few months if data is positive which could lead to more funding. $sgmo"
X Link 2025-04-04T15:53Z [---] followers, [---] engagements

"@BiotechAnalysst $ions mgmt should pick up this Angelman target from $sgmo to monopolize this treatment. Their ph2 data looked pretty good. Surprised that $biib gave it back. Probably don't want to pay the milestone. Ph3 is now on the way"
X Link 2025-04-04T19:01Z [---] followers, [---] engagements

"Looks like big pharmas are gearing up for the CNS. $ions $sgmo https://www.biopharmadive.com/news/gsk-abl-deal-neurodegenerative-diseases-brain-drug-research/744620/utm_source=Sailthru&utm_medium=email&utm_campaign=Issue:%202025-04-07%20BioPharma%20Dive%20%5Bissue:71982%5D&utm_term=BioPharma%20Dive https://www.biopharmadive.com/news/gsk-abl-deal-neurodegenerative-diseases-brain-drug-research/744620/utm_source=Sailthru&utm_medium=email&utm_campaign=Issue:%202025-04-07%20BioPharma%20Dive%20%5Bissue:71982%5D&utm_term=BioPharma%20Dive"
X Link 2025-04-07T22:00Z [---] followers, [----] engagements

"@ArtsStocks @AAMortazavi Don't believe Trump will allow China to sell copy cat drugs here in the U.S. to take advantage of our medical system here and destroy the biotech industry. $ions #TrumpTariffs"
X Link 2025-04-08T20:59Z [---] followers, [---] engagements

"$alny has a big gap to fill to around $166"
X Link 2025-04-09T15:03Z [---] followers, [--] engagements

"@ArtsStocks @AAMortazavi $sgmo $ions $arwr Watch for legislation from congress to protect the biotech industry https://www.biopharmadive.com/news/us-china-biotech-report-commission/744718/ https://www.biopharmadive.com/news/us-china-biotech-report-commission/744718/"
X Link 2025-04-09T20:04Z [---] followers, [----] engagements

"@GeneInvesting Looks like the new commissioner is a strong supporter for drug development $sgmo $arwr $ions"
X Link 2025-04-11T17:28Z [---] followers, [---] engagements

"@DM1research There CT for muscle and cardiac muscles should be coming out anytime now The 1st one should be the one partnered with $azn targeting cardiac muscles. $bcyc will likely get milestones from this. $ions $bcyc"
X Link 2025-04-11T22:39Z [---] followers, [---] engagements

"$sgmo $ions This should be a big deal to help treat Alzheimer patients and should make it easier for Alzheimer drug development. https://medicalxpress.com/news/2025-03-highly-accurate-blood-alzheimer-disease.html https://medicalxpress.com/news/2025-03-highly-accurate-blood-alzheimer-disease.html"
X Link 2025-04-14T02:32Z [---] followers, [----] engagements

"@BiotechAnalysst CDC should give some funding to $sgmo and $ions to speed up their prion program"
X Link 2025-04-16T17:13Z [---] followers, [---] engagements

"First interview with FDA Commissioner Marty Makary $sgmo $ions $arwr $ntla https://www.youtube.com/watchv=R4mojSYOTnQ https://www.youtube.com/watchv=R4mojSYOTnQ"
X Link 2025-04-18T02:31Z [---] followers, 10.3K engagements

"Biotech2k1's comment is a bit outdated. When was the last time he analyzed the company I don't believe he knows what type of tech $ions is using now and about to use. Did he look at the status of the pipeline and commercialized drugs Likely just a casual observer"
X Link 2025-04-20T17:26Z [---] followers, [---] engagements

"@BiotechAnalysst 9/ $sgmo Grok also answered the 2nd part of my question: Would Sangamo's current preclinical pipeline CNS targets (e.g. Alzheimer targeting MAPT Angelman etc. ) which uses ZFN would also work with their Bxb1"
X Link 2025-04-21T01:51Z [---] followers, [--] engagements

"@BiotechAnalysst 10/ $sgmo Grok also answered the 2nd part of my question: Would Sangamo's current preclinical pipeline CNS targets (e.g. Alzheimer targeting MAPT Angelman etc. ) which uses ZFN would also work with their Bxb1"
X Link 2025-04-21T01:53Z [---] followers, [---] engagements

"Marty Makary's vision for rare diseases should bode well for $ions CNS program"
X Link 2025-04-21T02:56Z [---] followers, [---] engagements

"$ions $ntla HAE patients are unsatisfied with current prophylactic treatment options https://www.morningstar.com/news/business-wire/20250429724102/new-harris-poll-findings-reveal-hae-patients-are-unsatisfied-with-current-prophylactic-treatment-options-with-over-90-interested-in-trying-new-therapies https://www.morningstar.com/news/business-wire/20250429724102/new-harris-poll-findings-reveal-hae-patients-are-unsatisfied-with-current-prophylactic-treatment-options-with-over-90-interested-in-trying-new-therapies"
X Link 2025-04-29T18:18Z [---] followers, [---] engagements

"@JungleJorge2 @Franca_ole @yusufhameed @grok $RGLS was created through a joint venture from $ions and $alny. They might still have ownership in $rgls. Not sure how they would handle the IP with potential acquisition. $sgmo"
X Link 2025-04-30T17:59Z [---] followers, [---] engagements

"@TradingStatsXYZ I haven't seen an open market purchase from an insider at $ions in a long time"
X Link 2025-05-03T13:21Z [---] followers, [--] engagements

"@GamalielBaer @Franca_ole Looks like $vrtx was going after larger transgene diseases like DMD (AAV packaging limit of [---] kb limits their use for larger transgenes). $sgmo ZFNs are smaller (0.30.6 kb) making them highly compatible with AAVs limited cargo capacity (4.7 kb)"
X Link 2025-05-05T02:11Z [---] followers, [---] engagements

"@GamalielBaer @Franca_ole Cargo size for: ZFN (0.30.6 kb) CRISPR/Cas9 (4.2 kb) or TALENs (1.72 kb). AAV vectors have a packaging limit of [---] kb which restricts their use except ZFN. I believe this is one of the reasons why companies are exiting gene therapy using AAV delivery. $sgmo $vtz $azn"
X Link 2025-05-05T02:30Z [---] followers, [---] engagements

"$ions $prax Preterm infant with drug-resistant seizures responds to antisense oligonucleotide treatment https://medicalxpress.com/news/2025-05-preterm-infant-drug-resistant-seizures.html https://medicalxpress.com/news/2025-05-preterm-infant-drug-resistant-seizures.html"
X Link 2025-05-05T20:10Z [---] followers, [----] engagements

"$ions $prax Clinical Updates from the Elsunersen Emergency Use Program: A Novel ASO for Treatment of Early Onset SCN2A Developmental and Epileptic Encephalopathy"
X Link 2025-05-05T20:19Z [---] followers, [---] engagements

"@ArtsStocks Not sure why $ions didn't list this on their partnered pipeline"
X Link 2025-05-05T20:25Z [---] followers, [---] engagements

"This is related to SCN2A. Looks good for $sgmo CNS pipeline Preterm infant with drug-resistant seizures responds to antisense oligonucleotide treatment https://medicalxpress.com/news/2025-05-preterm-infant-drug-resistant-seizures.html https://medicalxpress.com/news/2025-05-preterm-infant-drug-resistant-seizures.html"
X Link 2025-05-05T20:38Z [---] followers, [---] engagements

"@ArtsStocks @NationalAutism @US_FDA $sgmo also has this gene in their pipeline. $ions"
X Link 2025-05-05T21:01Z [---] followers, [---] engagements

"@ArtsStocks @AaronRosenblum5 @bearsbounce @seedy19tron Did $ions incorporated their MsPA chem into Donidalorsen"
X Link 2025-05-06T16:59Z [---] followers, [---] engagements

"@ArtsStocks @AaronRosenblum5 @bearsbounce @seedy19tron With MsPA dosing could go to around 6mos. Likely will be on their follow-on drug. $ions"
X Link 2025-05-06T17:56Z [---] followers, [---] engagements

"@yusufhameed @JohnCendpts @MartyMakary @SecKennedy @POTUS Listened to several of Dr. Vinay Prasad podcasts. So he disagreed with some of the decisions made by Peter Marks particularly on Sarepta's gene therapy and somehow this translated into that he is against gene therapy. $sgmo"
X Link 2025-05-06T19:27Z [---] followers, [---] engagements

"@yusufhameed @JohnCendpts @MartyMakary @SecKennedy @POTUS $sgmo $ions Dr. Vinay Prasad podcasts https://www.bing.com/videos/riverview/relatedvideoq=vinay+prasad&mid=3188A09B358D7B06F5283188A09B358D7B06F528&FORM=VIRE https://www.bing.com/videos/riverview/relatedvideoq=vinay+prasad&mid=3188A09B358D7B06F5283188A09B358D7B06F528&FORM=VIRE"
X Link 2025-05-06T19:41Z [---] followers, [---] engagements

"$ions $arwr $azn $amgn Largest study of lipoprotein(a) links any elevation to increased cardiovascular risk https://medicalxpress.com/news/2025-05-largest-lipoproteina-links-elevation-cardiovascular.html https://medicalxpress.com/news/2025-05-largest-lipoproteina-links-elevation-cardiovascular.html"
X Link 2025-05-07T21:37Z [---] followers, [---] engagements

"@ArtsStocks @oligogirl @AAMortazavi @christymaginn @OTSociety @bio_clouseau @Sanctuary_Bio @Sports_bios Looks like it will be $ions subcutaneous administration vs the others with intravenous adm"
X Link 2025-05-08T16:56Z [---] followers, [---] engagements

"@IgsabaF Likely countries with price control will be dropped and personnel will be terminated to keep the U.S. pricing at status quo. I see U.S. pricing could go higher too to cover lost market shr. Pharmas will have to evaluate which countries to sell to. $pfe $ions $arwr $alny $sgmo"
X Link 2025-05-12T00:56Z [---] followers, [----] engagements

"@IgsabaF It also will depend on what commercial stage of the drugs. If a drug that's newly approved pharmas will likely sell mainly to the U.S. market to keep the price high until new drug exclusivity expires. $pfe $ions $arwr $alny $sgmo"
X Link 2025-05-12T02:09Z [---] followers, [----] engagements

"@ionispharma Looks like $ions LICA drugs continues to show positive results LICA+new MsPA chem to come"
X Link 2025-05-19T14:05Z [---] followers, [---] engagements

"@Franca_ole $ions is the pioneer of developing drugs for CNS. They have drugs approved for SMA and SOD1 (ALS). MAPT phase [--] data should be coming out next year. High expectation for this target based on their phase [--] data. [--] ph2 CNS drugs. They've derisked many of the targets. $sgmo"
X Link 2025-06-03T23:50Z [---] followers, [---] engagements

"Good to hear from today's corp. update that $ions no longer list phase [--] CT on their pipeline list. This is to prevent competitors from copying their work. They will continue to rollout 5-6 preclinical drugs for CT. Seems like they've made lots of progress based on their Q&A"
X Link 2025-06-05T23:16Z [---] followers, [---] engagements

"@ArtsStocks After they have cleaned up the pipeline inventory list it seems like they didn't move any of the preclinical drugs to CT the last [--] yrs. It's impossible to follow what they have on early stage drugs. But I do understand their concerns about competitors looking at it. $ions"
X Link 2025-06-06T18:02Z [---] followers, [---] engagements

"This is a surprise. Looks like $ions has a siRNA molecule in CT right now and expect to have some data on it later the yr"
X Link 2025-06-09T18:53Z [---] followers, [---] engagements

"@ArtsStocks @business @barronsonline @WSJbusiness @WSJheard @CNBCFastMoney @MadMoneyOnCNBC They thought their non-conjugated ASOs were good enough to develop new drugs. They had to retool with conjugated version (LICA). BM has a new strategy for $ions. They now using ASOs siRNA and CRISPR. Next 3-10yrs will look much better with new tech adv. Much diff. company now"
X Link 2025-06-09T20:26Z [---] followers, [---] engagements

"@ArtsStocks @business @barronsonline @WSJbusiness @WSJheard @CNBCFastMoney @MadMoneyOnCNBC $ions BBB crossing tech is scheduled to start CT in [----]. Tox studies in [----] 1st drug will be wholly owned Looks like they have multiple CNS drugs lined up for this new platform"
X Link 2025-06-09T20:32Z [---] followers, [---] engagements

"@SuperDuperDrugs $ions has couple of follow-on drugs. They have already created a siRNA molecule for Lpa. $NVS had already accepted that molecule last yr. Likely they already have a siRNA for Olezarsen since this is wholly owned"
X Link 2025-06-11T17:30Z [---] followers, [--] engagements

"Wondering if this siRNA is ION775 $ions"
X Link 2025-06-11T18:03Z [---] followers, [---] engagements

"@BiotechAnalysst $ions MAPT for mild Alzheimer's ph2 data readout is scheduled for [----]. Should be an exciting event $sgmo $ions"
X Link 2025-06-12T15:06Z [---] followers, [---] engagements

"@RNAiAnalyst Interesting to see $ions is going after TTR and AGT using $MGX CRISPR tech. Likely to address the competition with $alny"
X Link 2025-06-16T18:38Z [---] followers, [---] engagements

"@RNAiAnalyst Wondering if one of the Undisclosed Cardiovascular Disease is a follow-on drug for Olezarsen using $mgx CRISPR. $ions"
X Link 2025-06-16T19:01Z [---] followers, [---] engagements

"@kargyriou1968 Setting up for some CT data read out on sHTG and polycythemia vera. $ions"
X Link 2025-06-18T14:34Z [---] followers, [---] engagements

"@RNAiAnalyst Not sure what their strategy on HAE's follow-on drug. $ions new MsPA chem could give their follow-on drug at least 6mos dosing schedule"
X Link 2025-06-18T16:36Z [---] followers, [---] engagements

"@TTRAmyloid Looks like most of $ions current CNS drugs in CT could qualify for CNPV. Is there a limit on the number of CNPV that FDA can give out @ionispharma"
X Link 2025-06-20T02:40Z [---] followers, [---] engagements

"@ArtsStocks @alsassociation @StanleyCrooke @US_FDA In some ways ALS is similar to SMA. If you treat them early like SMA patients you get much better results. $BIIB SOD1 CT on presymptomatic adults should confirm that theory. $ions"
X Link 2025-06-20T19:08Z [---] followers, [---] engagements

"@BiotechAnalysst I believe FDA will get rid of the traditional phase 1-3 CTs or modify it substantially. Companies' proven technology platform they talked about will also contribute to this shortened CTs. $sgmo $ions $arwr $ntla $beam $alny"
X Link 2025-06-22T17:18Z [---] followers, [----] engagements

"@richsprano @TTRAmyloid @ionispharma If ph2 data looks goods I suspect FDA could grant the drug conditional approval. Their ASO platform for CNS has proven to work and safe. $ions $biib"
X Link 2025-06-23T15:20Z [---] followers, [---] engagements

"@TTRAmyloid $ions is likely using the new backbone chem (MsPA) on the new SMA drug to obtain the annual dosing This bode well for the other CNS drugs too. Will the MsPA chem also improve their siRNA drugs too $biib"
X Link 2025-06-25T14:20Z [---] followers, [---] engagements

"@Franca_ole @TheCryptoMaze @BiotechAnalysst If $ions MAPT tau ph2 data looks good next year Genentech would be encouraged to start their CT shortly after. $sgmo"
X Link 2025-07-01T16:12Z [---] followers, [---] engagements

"Looks like Dogwood Therapeutics had reported positive data on Nav [---]. Can't find such data on-line They are currently doing a ph 2b. $sgmo https://www.biopharmadive.com/news/sodium-channels-pain-nav-opioid-vertex-startups/751996/utm_source=Sailthru&utm_medium=email&utm_campaign=Issue:%202025-07-01%20BioPharma%20Dive%20%5Bissue:74548%5D&utm_term=BioPharma%20Dive https://www.biopharmadive.com/news/sodium-channels-pain-nav-opioid-vertex-startups/751996/utm_source=Sailthru&utm_medium=email&utm_campaign=Issue:%202025-07-01%20BioPharma%20Dive%20%5Bissue:74548%5D&utm_term=BioPharma%20Dive"
X Link 2025-07-01T22:39Z [---] followers, [---] engagements

"@GamalielBaer @JungleJorge2 @jewcypickle Look for Roche to start CT after $ions MAPT ALZ ph2 read next year. $sgmo"
X Link 2025-07-19T21:19Z [---] followers, [---] engagements

"@ArtsStocks This is good news to help diagnose and treat Alzheimers patients. $sgmo $rhhby $ions $biib"
X Link 2025-07-22T20:43Z [---] followers, [---] engagements

"$azn reported $44m of sale this quarter on Wainua. $ions"
X Link 2025-07-29T18:46Z [---] followers, [---] engagements

"Wainua 1Q [----] sale was $39m. $azn $ions"
X Link 2025-07-29T18:50Z [---] followers, [---] engagements

"I'm surprised that $azn initiated phase 2b apolipoprotein L1 (APOL1) without a LICA $ions"
X Link 2025-07-30T15:06Z [---] followers, [---] engagements

"Salanersen for SMA very likely incorporating the MsPA chem to achieve the annual dosing. Great tech advancement $ions $biib"
X Link 2025-07-30T15:55Z [---] followers, [---] engagements

"Should be interesting for $ions investors. Innovation Day [----] Oct [--] [----] 8:30 AM EDT"
X Link 2025-08-02T13:52Z [---] followers, [---] engagements

"@ArtsStocks $ions deliberately designed their CT to give their drug an advantage over $alny when marketing the drug"
X Link 2025-08-02T14:01Z [---] followers, [---] engagements

"@RNAiAnalyst $mgx might come up on Innovation Day Oct [--]. $ions"
X Link 2025-08-02T14:33Z [---] followers, [----] engagements

"$lly and $vrtx could be interested in $sgmo Nav [---] to give them another target for chronic neuropathic pain. https://www.fiercebiotech.com/biotech/eli-lilly-shakes-pain-pipeline-part-quarterly-rd-clearoututm_medium=email&utm_source=nl&utm_campaign=LS-NL-FierceBiotech&oly_enc_id=6410A8494378C6A https://www.fiercebiotech.com/biotech/eli-lilly-shakes-pain-pipeline-part-quarterly-rd-clearoututm_medium=email&utm_source=nl&utm_campaign=LS-NL-FierceBiotech&oly_enc_id=6410A8494378C6A"
X Link 2025-08-07T17:02Z [---] followers, [---] engagements

"@ArtsStocks @Biotech2k1 has no idea what the advantage of ASO tech over siRNA. He failed to ask why siRNA can't do SMA while ASO can He also fails to follow the tech and pipeline adv from $ions. He is just a casual observer from the sideline like many others"
X Link 2025-08-14T23:51Z [---] followers, [---] engagements

"Some have speculated at least one Japanese pharma company is interested in $sgmo Fabry and other assets. What if they are waiting for the foreign exchange rate to be in their favor With interest rate coming down in the U.S. they might get a discount on the final price"
X Link 2025-08-23T04:10Z [---] followers, [---] engagements

"@Jake__Turnbull @Franca_ole Keep an eye on $ions / $biib ph2 data readout on IONIS-MAPT (BIIB080) next yr. If it looks good there it should encourage Roche to start their CT on the same target. $sgmo"
X Link 2025-08-28T19:51Z [---] followers, [---] engagements

"$ions is in a winning streak this past [--] yrs and likely will continue into 2016-2017 and beyond. Unlike the old days. Their LICA delivery makes the difference. BM's leadership and rest of his team are making the difference Still have several blockbuster drugs coming"
X Link 2025-09-02T16:47Z [---] followers, [---] engagements

"@MykeC382023 Both can coexist and lead the RNAi race. Look for $arwr to rise substantially in 2027-2028 when they start to show quarter to quarter revenue growth from their current drugs in late stage pipeline. $ions revenue growth has started recently"
X Link 2025-09-03T19:30Z [---] followers, [---] engagements

"@mchilberg @ShortsellerST Looks like the 2nd gen Stac-BBB capsids will not generate new licensing fees in the near term. $sgmo mgmt needs to be smarter on how to generate new license fees from their R&D"
X Link 2025-09-04T01:15Z [---] followers, [---] engagements

"$sgmo $qure"
X Link 2025-09-05T12:05Z [---] followers, [----] engagements

"@RNAiAnalyst Curious as to why they started with the highest dose $sgmo $qure"
X Link 2025-09-05T12:08Z [---] followers, [---] engagements

"Seems like every patients (n=4) have some type of SAE $sgmo $qure"
X Link 2025-09-05T12:17Z [---] followers, [---] engagements

"@ShortsellerST Why is $qure starting CT for a lower dose $sgmo"
X Link 2025-09-05T12:29Z [---] followers, [---] engagements

"Are the potential BPs waiting for the Fed rate cut/better currency exchange rate to finalize the Fabry deal $sgmo"
X Link 2025-09-07T16:39Z [---] followers, [---] engagements

"$ions $biib Do you think IONIS's MAPT will get accelerated FDA approval if phase [--] data shows evidence of cognitive improvement or other efficacies for patients with mild forms of Alzheimer/dementias"
X Link 2025-09-09T15:51Z [---] followers, [---] engagements

"Perhaps it's time to come to $sgmo for the next generation CNS delivery Will $lly continue to partner with Capsida or start their CNS program with $sgmo https://www.fiercebiotech.com/biotech/capsida-pauses-phase-1-gene-therapy-trial-after-child-diesutm_medium=email&utm_source=nl&utm_campaign=LS-NL-FierceBiotech&oly_enc_id=6410A8494378C6A https://www.fiercebiotech.com/biotech/capsida-pauses-phase-1-gene-therapy-trial-after-child-diesutm_medium=email&utm_source=nl&utm_campaign=LS-NL-FierceBiotech&oly_enc_id=6410A8494378C6A"
X Link 2025-09-11T16:32Z [---] followers, [----] engagements

"@FrankHulskof Looks like the earliest this patent litigation can begin is [--] days after the FDA accepts an BLA. $ions $arwr"
X Link 2025-09-11T19:42Z [---] followers, [---] engagements

"@Partimefriend @ArtsStocks @FrankHulskof @pikva63 @RNAiAnalyst Looks like WO 2012/149495 belongs to $ions"
X Link 2025-09-13T06:04Z [---] followers, [---] engagements

"@_johnnymaga The left is pushing her to be the next U.S. senator from NY I guess anyone now can be a U.S. senator. They have already lowered the bar to be a .U.S. house of representatives"
X Link 2025-10-16T17:45Z [---] followers, [--] engagements

"@RNAiAnalyst You don't think $ions IONIS-TTR-LRx will be able to compete"
X Link 2018-03-15T18:13Z [---] followers, [--] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing